Kornimate/medical-research-clean huggingface dataset:
machine learning models for prediction of acute kidney injury after noncardiac surgery

Conditions: Postoperative Acute Kidney Injury

Summary: acute kidney injury (aki) is a common surgical complication characterized by a rapid decline in renal function. patients with aki are at an increased risk of developing chronic kidney disease and end-stage renal disease, which has been associated with an increased risk of morbidity, mortality and financial burdens. identifying high-risk patients for postoperative aki early can facilitate the development of preventive and therapeutic management strategies, and prediction models can be helpful in this regard. the goal of this retrospective study is to develop prediction models for postoperative aki in noncardiac surgery using machine learning algorithms, and to simplify the models by including only preoperative variables or only important predictors.


Eligibility criteria:
inclusion criteria: * adult patients (age ≥ 18 years) who had a serum creatinine measurement within 10 days before surgery and at least one measurement within 7 days after surgery. * eligible surgeries encompassed general, thoracic, orthopedic, obstetric, gynecology, and neurosurgery procedures lasting longer than 1 hour exclusion criteria: * patients with concurrent cardiac, vascular, urological, or transplant surgeries. * patients with an american society of anesthesiologists (asa) physical status v. * patients with end-stage renal disease (i.e., a glomerular filtration rate \[egfr\] of 15 ml/min/1.73 m² or receiving hemodialysis).
detection of sars-cov-2 in semen of covid-19 positive males

Conditions: COVID-19; Sars-CoV2; Corona Virus Infection; Semen

Summary: the objectives of the study, are to describe detection of sars-cov-2 in the semen of covid-19 positive patients, the duration of positive semen and to investigate the impact on semen quality, thereby providing insights into the early impact on male reproductive function.

sars-cov-2 (severe acute respiratory syndrome coronavirus 2), a novel coronavirus reported in late december 2019 in wuhan, china, has spread world-wide with over 1,000,000 coronavirus disease 2019 (covid-19) cases reported. new developments in molecular virology and immunobiology of sars-cov-2, improve our understanding about covid-19 prevention, management, and possible long-term effects. although viral transmission occurs predominantly through respiratory droplets, sars-cov-2 has been isolated in blood samples and feces from covid-19 patients, raising questions about viral shedding in other bodily fluids, including semen, as well as alternative modes of transmission. the objectives are to describe detection of sars-cov-2 in the semen of covid-19 positive patients, the duration of positive semen and to investigate the impact on semen quality, thereby providing insights into the early impact on male reproductive function.

Eligibility criteria:
inclusion criteria: * male * pcr on nasopharyngeal swab positive for sars-cov-2 * age: ≥ 18y - ≤ 50y * signed informed consent * when undergoing art treatment: icsi treatment exclusion criteria: * negative test of sars-cov-2 on nasopharyngeal swab sample * history of immunosuppression * impossibility to deliver a semen sample at uz brussel on a weekly base * when undergoing art treatment: ivf treatment
safety and efficacy study of the nile pax drug-eluting coronary bifurcation stent

Conditions: Coronary Disease

Summary: the purpose of this trial is to assess the safety and efficacy of the nile pax® drug eluting coronary bifurcation stent system for the treatment of single de novo bifurcation lesions in native coronary arteries with a main branch reference vessel diameter of 2.5-3.5 mm and side branch reference vessel diameter of 2.0-3.0 mm.

the bipax clinical trial is a prospective, non-randomized, multicenter, clinical trial evaluating the investigational coronary bifurcation device nile pax® in patients with main branch reference vessel diameters \>= 2.5 mm and \ = 2.0 and \<= 3.0 and lesion length \<= 14 mm. the trial allows the treatment of a single de novo bifurcation lesion in native coronary arteries following the provisional t-stenting technique with mandatory pre-dilatation of the main branch. in case the side branch requires a stent the treatment will be completed when possible with a delta pax® drug eluting side branch stent. the bipax clinical trial will enroll 100 patients. all patients will receive quantitative coronary angiography (qca) after stent implantation and at 9 months follow-up. all patients will have a clinical follow-up at 1, 6, 9 and 12 months and subsequently every year up to 5 years.

Eligibility criteria:
inclusion criteria: * de novo bifurcation lesions following the medina classification except (0,0,1). * maximum one bifurcation lesion per patient. * single bifurcation lesion per vessel. * the patient is at least 18 years of age. the patient has clinical evidence of ischemic heart disease, stable or unstable angina, silent ischemia, or a positive functional trial. * the patient is an acceptable candidate for percutaneous transluminal coronary angioplasty (ptca), stenting, and emergent coronary artery bypass graft (cabg) surgery. * the patient or patient's legal representative has been informed of the nature of the trial and agrees to its provisions and has provided written informed consent as approved by the institutional review board/ethics committee (irb/ec) of the respective clinical site. * the patient agrees to return to the same research facility for all required post-procedure follow-up visits. exclusion criteria: * de novo bifurcation lesion medina (0,0,1). * left main bifurcation. * heavily calcified lesions. * severe tortuous lesions. * documented left ventricular ejection fraction (lvef) \< 30% at most recent evaluation. * women of childbearing potential. * chronic total occlusion (cto). * previous pci of the target lesion. * second lesion requiring treatment in target vessel. * second bifurcation lesion requiring treatment. * currently participating in an investigational drug or another device trial that has not completed the primary endpoint or that clinically interferes with the current trial endpoints; or requires coronary angiography, ivus or other coronary artery imaging procedures.

Keywords: bifurcation dedicated drug-eluting stent angioplasty coronary artery disease coronary artery stenosis
intravenous exenatide in coronary intensive care unit (icu) patients

Conditions: Hyperglycemia; Acute Coronary Syndromes; Myocardial Infarction

Summary: the purpose of this study is to determine the efficacy of intravenous exenatide therapy in hyperglycemic patients admitted to the coronary intensive care unit.

diabetic patients with acute myocardial infarction (mi) have particularly poor outcomes. clinical practice guidelines from the american college of cardiology/american heart association for the treatment of patients with acute coronary syndromes call for treatment to achieve preprandial glucose \<110 mg/dl, a maximum daily target \<180 mg/dl, and a post-discharge hemoglobin a1c \<7%. initiation of aggressive insulin therapy is also warranted to achieve blood glucose \<150 mg/dl during days 0-3 and 80-110 mg/dl when possible thereafter. to date, no studies have been conducted assessing the efficacy of intravenous exenatide administration on achieving glucose lowering in hyperglycemic coronary icu patients.

Eligibility criteria:
inclusion criteria: * admission to coronary icu * admission blood glucose 140-299 mg/dl * primary cardiovascular diagnosis by attending physician * under primary care of cardiology service * age \> 18 years old * ventilator independent * able to provide informed consent exclusion criteria: * admission blood glucose \ 300 mg/dl * ventilator dependent * unconscious sedation * type 1 diabetes * known pregnancy * admitted to coronary icu for right heart cath to measure hemodynamics prior to transplant * post transplant procedure * currently enrolled in another clinical trial * unable to provide informed consent * creatinine clearance \< 30 ml/min * on insulin treatment except for monotherapy with long-acting basal insulin (e.g., insulin glargine \[lantus®\] or detemir \[levemir®\]) * gastroparesis

Keywords: hyperglycemia acute coronary syndromes myocardial infarction
cannabis for spasticity in multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the purpose of this study is to learn if the use of inhaled cannabis (marijuana) and oral cannabinoid (dronabinol, marinol or thc, which is an active ingredient of marijuana) is safe and effective in reducing the symptoms of spasticity and tremor in patients with secondary-progressive or primary progressive multiple sclerosis.

the treatment of ms is far from satisfactory. for acute attacks, high dose corticosteroids seem to reduce the duration of attacks and to reduce the likelihood of future attacks. immunomodulatory agents, available in this disease over the last decade, reduce the frequency of severe attacks by about one third. the remainder of the treatments are symptomatic, aimed at reducing the disability already present. recent research into the cb1 and cb2 cannabinoid receptor systems suggest that cannabis may have the potential for affecting both the pathogenic mechanisms and the symptoms of ms. in light of the autoimmune hypothesis of the etiology of ms, thc could directly alter immune function in a manner that might reduce (or increase) the primary pathology of the disease. comparisons: three treatment arms will be compared: 1. inhaled cannabis and oral placebo 2. inhaled placebo and oral thc 3. inhaled placebo and oral placebo the effects of these agents analyzed at 3 weeks and 7 weeks.

Eligibility criteria:
inclusion criteria: * diagnosis of clinically definite multiple sclerosis as defined by poser criteria * moderate or severe spasticity * age 21 or older * must live close to the sacramento, ca area exclusion criteria: * preexisting pulmonary conditions, including poorly controlled asthma, chronic bronchitis, emphysema, bronchiectasis, and other significant pulmonary disorders * preexisting cardiac conditions, including ischemic heart disease, congestive heart failure, and other significant cardiac disorders * inability to abstain from tobacco or marijuana smoking, or use of alcohol or sedative or hypnotic medications during the duration of the study * pre-existing dementia, mania, depression or schizophrenia or other poorly controlled psychiatric illness * past history of abuse of recreational drugs, including marijuana and alcohol in the last 12 months * history of or currently meets dsm-iv criteria for dependence on cannabis * use of cannabis, marijuana, or thc in the last four weeks * preexisting dementia, mania, depression, or schizophrenia or other poorly controlled psychiatric illness * exacerbation of ms within 30 days prior to screening visit * current use of cyclophosphamide, mitoxantrone, or cladribine * arthritis, bony and soft tissue disorders interfering with spasticity measures * inability to provide informed consent * recent cannabis use of more than twice per week one month prior to study entry * for females of child bearing potential, inability to comply with adequate contraception

Keywords: cannabis marijuana multiple sclerosis spasticity
m-tapa block for laparoscopic cholesistectomy

Conditions: Cholecystitis; Cholecystitis, Acute; Cholecystitis, Chronic

Summary: modified perichondral approach thoracoabdominal nerve (m-tapa) block is a novel block that provides effective analgesia of the anterior and lateral thoracoabdominal walls during laparoscopic surgery, in which local anesthetic is applied only to the lower side of the perichondral surface. m-tapa block is a good alternative for analgesia of the upper dermatome levels and the abdominal lateral wall, and may be an opioid-sparing strategy with satisfactory quality improvement in patients undergoing laparoscopic surgery.

modified perichondral approach thoracoabdominal nerve (m-tapa) block is a novel block that provides effective analgesia of the anterior and lateral thoracoabdominal walls during laparoscopic surgery, in which local anesthetic is applied only to the lower side of the perichondral surface. m-tapa block is a good alternative for analgesia of the upper dermatome levels and the abdominal lateral wall, and may be an opioid-sparing strategy with satisfactory quality improvement in patients undergoing laparoscopic surgery. m-tapa block provides analgesia at the level of t5-t11 in the abdominal region. sonoanatomy is easy to visualize and the spread of local anesthetic can be easily seen. analgesia occurs in several dermatomes thanks to the cephalocaudal spread of the local anesthetic solution. there are studies in the literature investigating the effectiveness of m-tapa block for post-operative pain management in bariatric surgery. in this study, the investigators aimed to evaluate the effectiveness of m-tapa block for postoperative analgesia management after laparoscopic cholecystectomy surgery.primary aim is to compare the postoperative pain scores (vas), and secondary aim is to compare the postoperative rescue analgesic use and postoperative opioid consumption, and the side effects (allergic reaction, nausea, vomiting) associated with opioid use.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) classification i-ii * scheduled for laparoscopic cholesistectomy surgery under general anesthesia exclusion criteria: * bleeding diathesis * receiving anticoagulant treatment * known local anesthetics and opioid allergy * infection of the skin at the site of the needle puncture * pregnancy or lactation * patients who do not accept the procedure

Keywords: laparoscopic cholesistectomy m-tapa block postoperative analgesia
intraoral scanners as periodontal and dental pathologies diagnosis tools

Conditions: Periodontitis; Gingivitis; Dental Caries; Diagnosis

Summary: periodontal diseases and dental pathologies are highly prevalent oral diseases. thirty-three to fifty percent of adult population presented at least one untreated caries and more than 50% of french population are affected by severe periodontitis. these diseases affect dental organ or periodontal attached system but could have negative impact on general health, quality of life, word and individual well-being. association between chronic diseases as diabetes, rheumatoid arthritis, cardiovascular diseases, and oral health have been well investigated. dental and periodontal diagnosis is dependent of various clinical parameters time consuming and dependent operator. it represents a public health challenge. informatic analysis detecting diseases could be a time gain and a more precise diagnosis tool. today, any software or algorithm allow automatized detection, clinical qualitative or quantitative indices recording while these informations are present in numeric models

the present study explores the effectiveness of intraoral scanners in the field of dental caries and periodontal diseases diagnosis patients presenting at least on recession are recruited without randomization. a clinical examination is performed, and a 3d impression of their mouth is obtained by intraoral scanners. the investigators hypothesized that the 3d intra oral representations could improve oral diagnosis in patients compared to clinical examination in term of time consummation and precision. in a first time, this could be achieved by the comparison of the recession measurement obtained by a clinical measure (ramfjord, 1959) or obtained by artificial intelligence. the secondary objectives are : * to compare clinical and numerical dento-prosthetic diagram * to compare clinical and numerical plaque control record index (o'leary et al., 1973) * to compare clinical and numerical decayed, missed and filled teeth index (klein and palmer, 1940) * to compare clinical and numerical detection of mucosal lesions

Eligibility criteria:
inclusion criteria: * adultes * consulting the dental care service of the university hospital of reims * presenting at least one gingival recession * presenting at least 10 pairs of opposing teeth * speaking french * who signed the informed consent form * affiliated to the french social security system exclusion criteria: patients presenting : * pregnancy or breastfeeding * orthodontic treatments * patients under legal protection, trusteeship or guardianship * unable to understand auto-questionnary

Keywords: periodontal diseases dental caries intra-oral camera diagnosis
anterior lamellar recession vs bilamellar tarsal rotation in upper lid cicatricial trichiasis

Conditions: Cicatricial Trichiasis

Summary: in recent years there has been a significant shift from this destructive procedure to a reconstructive procedure such as anterior lamellar recession (alr) and bilamellar tarsal rotation (bltr).


Eligibility criteria:
inclusion criteria: * patients with upper lid cicatricial trichiasis that requires surgical intervention exclusion criteria: * refusal of the patients. * associated entropion., 3) severe ocular surface disease. * previous eyelid surgery. * associated lid laxity. * lack of adequate follow-up
pediatric long-term follow-up and rollover study

Conditions: Diffuse Astrocytoma; Anaplastic Astrocytoma; Astrocytoma; Oligodendroglioma, Childhood; Anaplastic Oligodendroglioma; Glioblastoma; Pilocytic Astrocytoma; Giant Cell Astrocytoma; Pleomorphic Xanthoastrocytoma; Anaplastic Pleomorphic Xanthoastrocytoma; Angiocentric Glioma; Chordoid Glioma of Third Ventricle; Gangliocytoma; Ganglioglioma; Anaplastic Ganglioglioma; Dysplastic Gangliocytoma of Cerebrellum; Desmoplastic Infantile Astrocytoma and Ganglioglioma; Papillary Glioneuronal Tumor; Rosette-forming Glioneuronal Tumor; Central Neurocytoma; Extraventricular Neurocytoma; Cerebellar Liponeurocytoma; Neurofibromatosis Type 1

Summary: a roll-over study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib.


Eligibility criteria:
key inclusion criteria: all subjects: * written informed consent, according to local guidelines, signed by the subjects and/or by the parents or legal guardian prior to any study related screening procedures are performed. * participation in a novartis sponsored study such as ctmt212x2101, cdrb436g2201, cdrb436a2102, regardless of current age. * parent study (or cohort of parent study) is planned to be closed. * subject has demonstrated compliance, as assessed by the investigator, within the parent study protocol requirement(s). * willingness and ability to comply with scheduled visits, treatment plans and any other study procedures. for subjects entering the treatment period: * subject is currently receiving treatment with dabrafenib/trametinib monotherapy or combination within a novartis sponsored drug development study. note that subjects who were on the chemotherapy arm of the cdrb436g2201 study are eligible for treatment period of this study only after crossing over into the experimental treatment arm of the cdrb436g2201 study * in the opinion of the investigator is likely to benefit from continued treatment. key exclusion criteria: all subjects: - subject has participated in a combination trial where dabrafenib and/or trametinib was dispensed in combination with another study medication. for subjects entering the treatment period: * subject has permanently discontinued from study treatment in the parent protocol due to any reason. * treatment with dabrafenib and/or trametinib for the subject's indication is approved for marketing and the appropriate dosage form is commercially available and reimbursed in the local country * subject currently has unresolved drug related severe toxicities for which dabrafenib and/or trametinib dosing has been interrupted in the parent study. if the subject should meet criteria to resume treatment on the parent protocol then they may be eligible for treatment in this study. other protocol-defined inclusion/exclusion may apply.

Keywords: v600-mutation neuroblastoma trametinib pediatrics langerhans cell histiocytosis low grade glioma plexiform neurofibromas high grade glioma dabrafenib nf-1
chemotherapy with monoclonal antibody and radioimmunotherapy for high-risk b-cell non-hodgkins lymphoma

Conditions: Lymphoma, B-Cell

Summary: the purpose of this study is to determine whether using high-dose chemotherapy, monoclonal antibodies, and targeted radioimmunotherapy will slow the progression of disease in patients with high-risk non-hodgkin's lymphoma (nhl).

this is a phase ii efficacy trial for patients with untreated, high-risk, b-cell non-hodgkin's lymphoma. the study will evaluate the efficacy and safety of high-dose chemotherapy combined with monoclonal antibodies and targeted radioimmunotherapy in previously untreated patients with high-risk nhl

Eligibility criteria:
inclusion criteria: * untreated, biopsy proven b-cell non-hodgkin's lymphoma * age \>/= 18 years * no other prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for one year. the patient cannot have been exposed to chemotherapy to treat any of these diseases for at least 3 years prior to study entry. * meet staging studies and laboratory tests prior to induction, consolidation and radioimmunotherapy. exclusion criteria: * significant medical and/or psychiatric illness which may compromise planned treatment; * pregnant or lactating; * hiv-infection. * patients with follicular lymphoma grade 1, 2 or 3a are not eligible for this trial.

Keywords: high risk non-hodgkins lymphoma nhl bexxar high dose chemotherapy
vanguard tka with kneealign 2 and without kneealign 2

Conditions: Osteoarthritis, Knee

Summary: purpose of this study is to determine the effectiveness of the kneealign 2 system in terms of precise implant alignment by demonstrating that kneealign 2 provides better tibial alignment compared to conventional instruments

purpose of this study is to determine the effectiveness of the kneealign 2 system in terms of precise implant alignment by demonstrating that kneealign 2 provides better tibial alignment compared to conventional instruments.

Eligibility criteria:
inclusion criteria: * knee (either unilateral or bilateral) osteoarthritis (varus deformity only) * subjects willing to return for follow-up evaluations exclusion criteria: * knee degenerative diseases other than knee osteoarthritis (such as necrosis / rheumatoid arthritis) * severe oa deformation (fta: \>185 degrees or \<175 degrees) * active infection (or within 6 weeks after infection) * sepsis * osteomyelitis * any type of implant is inserted in the affected side of lower extremity * hip disease on the affected side * uncooperative patient or patient with neurologic disorders who are incapable of following directions * diagnosed osteoporosis or osteomalacia * metabolic disorders which may impair bone formation * distant foci of infections which may spread to the implant site * rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram * vascular insufficiency, muscular atrophy or neuromuscular disease.

Keywords: navigation system palm-sized total knee arthroplasty